Skip to content

The safety and effectiveness of esketamine combined with dexmedetomidine nasal drops for children sedation

The safety and effectiveness of esketamine combined with dexmedetomidine nasal drops for children sedation

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100043960
Enrollment
Unknown
Registered
2021-03-06
Start date
2021-03-01
Completion date
Unknown
Last updated
2021-07-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Children sedation

Interventions

Group DS:Dexmedetomidine combined with esketamine nasal drops

Sponsors

Huai'an Maternity and Child Hleathcare Hospital
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
1 Years to 6 Years

Inclusion criteria

Inclusion criteria: Select 126 children who need to be sedated, aged 1-6 years, weight 9-21kg, ASA classification I-II.

Exclusion criteria

Exclusion criteria: Patients who refuse to sign informed consent to participate in the trial; patients with upper respiratory tract infections; asthmatics; those who are allergic to Dex or esketamine; those with mental disorders; those with elevated intracranial pressure; conduction block; emergency surgery; other situations that the researcher thinks are not suitable to participate in the study.

Design outcomes

Primary

MeasureTime frame
MOAA/S sedation score 30 minutes after administration;

Secondary

MeasureTime frame
onset time;Parents' Separation Anxiety Scale Score at 30min after adminstration;MaskAcceptance Scale Score 30 minutes after adminstration;Adverse reactions 24h after surgery;

Countries

China

Contacts

Public ContactJian Sun

Huai'an Maternity and Child Hleathcare Hospital

sjcxl1979@163.com+86 15996168372

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026